Skip to content

The compression of Misoprostol effect with and without Letrozole in first trimester abortion: A randomized clinical trial study

The compression of Misoprostol effect with and without Letrozole in first trimester abortion: A randomized clinical trial study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201412111760N37
Enrollment
140
Registered
2014-12-22
Start date
2014-01-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Termination of pregnancy in the first trimester. Termination of pregnancy, fetus and newborn

Interventions

Intervention 1: Intervention Group: In the Intervention group treatment is being performed on an out-patient basis for 2 days with Letrozole (made by Iran Hormone Co.) as 7.5 mg orally once a day, a
Treatment - Drugs
Placebo
Intervention Group: In the Intervention group treatment is being performed on an out-patient basis for 2 days with Letrozole (made by Iran Hormone Co.) as 7.5 mg orally once a day, and on the third
Control Group: In the control group treatment is being performed by placebo (folic acid as single blind – made by Iran Daru Co.) for 2 days and on the third day 800 mcg vaginal Misoprostol is being

Sponsors

Vice Chancellor for Research and Technology, Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Following 12 weeks of pregnancy; Reason for termination of pregnancy, such as missed abortion; Pregnancy NULL; Therapeutic abortion legal authorization and consent of patients Exclusion criteria: Pain and bleeding; Drug sensitivity to misoprostol; Severe anemia; Coagulopathy or taking anticoagulants; Active liver disease; Cardiovascular disease and uncontrolled seizures; Adrenal disease, or a history of corticosteroid use

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Abortion. Timepoint: The start of the intervention up to 24. Method of measurement: Ultrasound.;Time between medication abortion. Timepoint: The start of the intervention up to 24. Method of measurement: Ultrasound.;The need for curettage. Timepoint: Seven days after abortion. Method of measurement: Clinical.

Secondary

MeasureTime frame
Side effects. Timepoint: Intervention to 24 hours after administration. Method of measurement: Clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Zeinab Azmoodeh Fard

Babol University of Medical Sciences

zeinabazmoodeh@yahoo.com+98 11 3223 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026